Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...

Today, Benzinga's options scanner spotted 9 options trades for Amgen. This is not a typical pattern. The sentiment among ...

Fintel reports that on November 14, 2025, Piper Sandler maintained coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

The stock of pharmaceutical company Amgen (NASDAQ: AMGN) didn't exactly have a banner trading session on Thursday. In closing ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 194 % ...

Esperion faces pressure from emerging oral PCSK9i and CETP inhibitors, which offer superior LDL-c lowering. See why I rate ...

A powerful combination of unexpectedly robust quarterly earnings and groundbreaking clinical trial results has positioned ...

Amgen (AMGN) is a top biotech value pick with strong sales, robust R&D, and resilient growth. Read here for an analysis of ...

Look, I think Amgen needs to do something because they’ve gotta broaden the portfolio where they need to be able to tell a little bit better story about some of the things that, they have a lot ...